Event > Webinar >
Go/No-Go
Gaining mechanistic insights of toxicity using a human DILI microphysiological system to inform decision making
Abstract
A large proportion of drug attrition is caused by drug-induced liver injury (DILI). Whilst safety concerns account for 30% of all drug development failures, 18% are specifically due to hepatotoxicity.
Although traditional preclinical models capture intrinsic (simple, dose-dependent) DILI events, they cannot predict or unlock the mechanism of complex human DILI. As a result, indirect or idiosyncratic DILI risks can pass undetected through preclinical and clinical testing – causing financial and reputation losses for drug developers.
In this webinar, we demonstrate how to further de-risk your workflows with the PhysioMimix® DILI assay. Using drugs that were identified as toxic in the clinic, we reveal some of the data-rich investigative toxicology studies that can be achieved using a human liver microphysiological system (MPS), otherwise known as organ-on-a-chip (OOC).
The approach enables drug developers to explore the differing ways that drugs induce DILI including; oxidative stress, mitochondrial dysfunction, steatosis, dysregulation of bile acid synthesis or transport and inflammatory response.
We will discuss how these deep mechanistic insights empower better informed decisions that guide modified drug design and de-risk the clinical progression of future drug candidates.
Learning Objectives:
- Learn how the PhysioMimix human Liver MPS recapitulates organ functionality.
- Discover how to apply the PhysioMimix DILI assay to predict human risk
- Use of the assay to identify different mechanisms of DILI
- Understand where MPS fits within the drug discovery and development pipeline.
About the Presenter
Ovi
Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed on several assay development projects as lead biological scientist, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During time spent in the pharma industry he contributed to delivering high quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.